Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026850 (muscular dystrophy)
 5,870 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The protease inhibitor leupeptin decreases protein degradation in rat skeletal and cardiac muscle incubated in vitro, while protein synthesis remains unaltered. Leupeptin also lowers protein breakdown in denervated rat muscles and affected muscles from mice with hereditary muscular dystrophy. Leupeptin may thus be useful in retarding tissue atrophy. Since homogenates of leupeptin-treated muscles had decreased cathepsin B activity, this lysosomal protease may play a role in protein turnover in normal and diseased muscles.
 ...
PMID:Leupeptin, a protease inhibitor, decreases protein degradation in normal and diseased muscles. 62 52

A high-performance liquid chromatographic method is described for the determination of leupeptin, a possible therapeutic drug for muscular dystrophy, in mouse serum and muscle. Leupeptin is reduced with sodium borohydride to leupeptinol, and then converted to a fluorescent derivative with benzoin. The derivative is separated on a reversed-phase column (LiChrosorb RP-18) with isocratic elution and determined with fluorescence detection. The detection limits of leupeptin in serum and muscle are 250 pmol/ml (107 ng/ml) and 500 pmol/g (214 ng/g), respectively, corresponding to approximately 150 fmol each in a 100-microliters injection volume. This method is simple and sensitive enough to permit the quantification of leupeptin in biological samples from mice dosed with leupeptin.
 ...
PMID:High-performance liquid chromatographic method for monitoring leupeptin in mouse serum and muscle by pre-column fluorescence derivatization with benzoin. 408 97

Leupeptin is a potent inhibitor of cathepsin B in vitro and is presumed to act in a similar manner in vivo. It is currently being used in several laboratories to examine the role of lysosomal proteinases such as cathepsin B in mouse models of muscular dystrophy. This report clearly demonstrates that leupeptin in adequate concentrations in vivo, is a potent stimulator of cathepsin B activity in striated muscle, heart, liver and kidney of the mouse. This paradoxical effect indicates that care is required in the interpretation of the results of the use of leupeptin as a cathepsin B inhibitor in vivo and that its use as an antiprotease for therapeutic purposes may be limited. Studies on CBZ-Phe-Ala-CHN2 demonstrated that this agent, when administered in vivo, inhibited Cathepsin B in the tissues assayed.
 ...
PMID:Paradoxical effect of leupeptin in vivo on cathepsin B activity. 683 21

Mice with genetic muscular dystrophy were treated with intraperitoneal injections of the proteinase inhibitor leupeptin, beginning before the onset of weakness. A significant number of the treated animals failed to develop histological evidence of dystrophy, compared with controls. Leupeptin treatment prevented (or delayed) the onset of muscular dystrophy in this experiment.
 ...
PMID:Successful treatment of murine muscular dystrophy with the proteinase inhibitor leupeptin. 695 Apr 12